Monday 1 July 2024

The Pharma Letter Podcast — Episode 23 — AAIC preview with Eisai deputy CCO Michael Irizarry

Biotechnology
Simon Wentworth
6 July 2023
podcast-23-large

More on this story...

Biotechnology
Novel drug launches will lift global Alzheimer's disease market $13.7 billion in 2030
8 June 2023
Pharmaceutical
Otsuka tees up Japanese filing for brexpiprazole in Alzheimer's agitation
28 June 2023
Biotechnology
New Alzheimer's therapies ready for battle at AAIC 2023
12 July 2023
Pharmaceutical
BRIEF—Eisai divest two drugs to Kaken
29 March 2024


Related Company News

Eisai’s strategic collaboration with Bristol Myers Squibb ended
Alzheimer’s drug Leqembi launched in China
EU taking action to tackle GLP-1 receptor agonist shortages
BRIEF—TGA update on GLP-1 RAs pharmacy compounding changes
More ones to watch >


Today's issue

Pharmaceutical
Boosting crinecerfont, Neurocrine draws from gamut of FDA support
1 July 2024
Biotechnology
Forbion expands to Boston, hires former Dyne CEO
1 July 2024
Pharmaceutical
In ALS, Phase II data show two drugs could be better than one
1 July 2024
Biotechnology
Another win for nipocalimab as J&J closes in on rivals
1 July 2024
Pharmaceutical
Merck & Co sees value in novel prostate cancer drug
1 July 2024
Biotechnology
New Ajovy data challenges treatment breaks in migraine prevention
1 July 2024
Biotechnology
Zenas BioPharma appoints Orlando Oliveira as CCO
1 July 2024

Company Spotlight

A commercial stage biopharmaceutical R&D company, focused on the development of products that address the medical challenges in the therapeutic area of anti-infectives.




More Features in Biotechnology

Forbion expands to Boston, hires former Dyne CEO
1 July 2024
Another win for nipocalimab as J&J closes in on rivals
1 July 2024
New Ajovy data challenges treatment breaks in migraine prevention
1 July 2024
Zenas BioPharma appoints Orlando Oliveira as CCO
1 July 2024


Copyright © The Pharma Letter 2024   |   Headless Content Management with Blaze